Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

RECOMMENDED

Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Heart Assoc

Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, Wagner J, Philip S, Abrahamson D, Granowitz C, Go AS

doi: 10.1161/JAHA.120.020377

Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention

doi: 10.1371/journal.pone.0211464.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up

Circulation.

Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK

doi: 10.1161/

Heart, Artery and Coronary Diseases

Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The Multi-Ethnic Study of Atherosclerosis (MESA)

Circulation.

Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, Budoff M, Blumenthal RS, Yeboah J, Duprez DA, Mortensen MB, Dzaye O, Hong J, Nasir K, Blaha MJ

doi: 10.1161/CIRCULATIONAHA.119.045010.

Heart, Artery and Coronary Diseases

Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention

JAMA Cardiol.

Mortensen MB, Blaha MJ, Nordestgaard BG

doi: 10.1001/jamacardio.2019.4759.

Cardiovascular Risk and Diseases

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

Lancet.

Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R

doi: 10.1016/S0140-6736(19)31791-X.

Cardiovascular Risk and DiseasesAtrial FibrillationHeart, Artery and Coronary DiseasesHeart FailureHypertensionThrombosis and Stroke

Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis

Lancet Diabetes Endocrinol.

Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P

Heart Failure

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

ESC Heart Fail

Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, Khan SS, Baldridge AS, Shah SJ, Huang Y, Li C, Figtree GA, Perkovic V, Jardine MJ, Neal B, Huffman MD

doi: 10.1002/ehf2.13236

Myocardial InfarctionThrombosis and StrokeTherapy and Intervention

Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study